Results 51 to 60 of about 926 (182)

Forest plot of comparison of saroglitazar 4mg versus control on LDL-cholesterol (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus control on LDL-cholesterol (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source

Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Non-alcoholic fatty liver disease (NAFLD) is the most common liver-related metabolic disorder in the world, with a global prevalence of 25%.
Reza Afarin, Negar Dinarvand, Bahar Jaberian Asl, Ghazal Orak, Elham Shakerian, Fatemeh Bineshfar, Akram Ahangarpour   +6 more
doaj   +1 more source

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach

, 2023
Antidiabetic drugs that have a secondary pharmacological effect on angiogenesis inhibition may help diabetic patients delay or avoid comorbidities caused by angiogenesis including malignancies. In recent studies, saroglitazar has exhibited antiangiogenic
Sabina Khan (15333120), Sabina Khan, Swarna Dabral, Imran Ahmd Khan, Swarna Dabral (15333114), Prem Prakash, Nilanjan Saha, Suhel Parvez, Nilanjan Saha (3541379), Suhel Parvez (269139), Tarun Pant, Imran Ahmd Khan (15333117), Tarun Pant (3936983), Prem Prakash (435679)   +13 more
core   +1 more source

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Cardiovascular Diabetology, 2019
Background Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively.
Upendra Kaul, Deven Parmar, K. Manjunath, Mitesh Shah, Krupi Parmar, Kishor P. Patil, Ashok Jaiswal   +6 more
doaj   +1 more source

Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia - A Review [PDF]

Journal of Young Pharmacists, 2014
Diabetes mellitus is a worldwide prevalent chronic disease with a significant disease burden. The associated dyslipidemia adds to the lethality of type 2 diabetes mellitus and requires newer and better treatment strategies. Peroxisome proliferator activated receptor (PPAR) α and γ agonists are approved hypolipidemic and anti-diabetic agents ...
Arun Sharma, Amarnath S, Devendra Singh Kushwah, Ramaswamy S   +3 more
openaire   +1 more source

Forest plot of comparison of saroglitazar 4mg versus control on total cholesterol (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus control on total cholesterol (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source

Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Diabetic dyslipidaemia poses a therapeutic challenge. New therapies have emerged in this patient subgroup to enhance outcome and improve compliance.
Arijit Ghosh, Pranab Kumar Sahana, Chanchal Das, Ananya Mandal, Nilanjan Sengupta   +4 more
doaj   +1 more source

PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis

Journal of International Medical Research, 2023
Objective To undertake a network meta-analysis to compare the relative efficacy of a dual peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonist, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin in patients with non ...
Zhuo-Ya Zhang, Qi Yan, Wen-Hao Wu, Yuan Zhao, Hua Zhang, Jin Li   +5 more
doaj   +1 more source

Randomized Controlled Trial Evidence on Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. [PDF]

Int J Hepatol
Purpose Primary biliary cholangitis (PBC), an autoimmune liver disease, has the potential to advance to liver cirrhosis and result in fatality. Ursodeoxycholic acid (UDCA) is the first‐line treatment, while obeticholic acid (OCA) serves as a second‐line option because of moderate UDCA nonresponsiveness and cirrhosis‐related concerns.
Dar MS, Fatima T, Azhar SD, Rehman Z, Affan M, Saleem YM, Ali S, Athar F, Ishaq S, Ain NU, Zahid J, Khan AW, Ovais H, Ahmad TKF, Ahmed KAHM, Bharadwaj HR.   +15 more
europepmc   +2 more sources

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

, 2017
Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide.
Das, Nabanita, Prabodha Swain, Ranvir, Ramchandra, Eshani Karmakar, Roy, Sib Sankar, Rathod, Rohan, Wahli, Walter, Nabanita Das, Chitrang Trivedi, Walter Wahli, Jain, Mukul R., Suresh R. Giri, Ramchandra Ranvir, Akshyaya Rath, Pankaj R. Patel, Karmakar, Eshani, Patel, Pankaj R., Giri, Suresh R., Kadam, Shekhar, Bhoi, Bibhuti, Mukul R. Jain, Bibhuti Bhoi, Swain, Prabodha, Rohan Rathod, Shekhar Kadam, Patel, Hiren, Hiren Patel, Trivedi, Chitrang, Rath, Akshyaya, Sib Sankar Roy   +29 more
core   +1 more source